BIOBOHEMIA
This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use.
I accept
Close

Novel Antigen Compositions

Produced by Antigenic Essence Technology
For the Treatment of Oncological Diseases by Vaccination

Novel Antigen Compositions
Produced by Antigenic Essence Technology For the Treatment of Oncological Diseases by Vaccination

See our latest scientific paper
Petr G. Lokhov; Elena E. Balashova: "Antigenic Essence: Upgrade of Cellular Cancer Vaccines". Cancers 2021, 13, 774.
Early cancer vaccines include whole-cell formulations, which operate on the principle that you should vaccinate with what you want to develop protection against. Such vaccines have been widely tested in various cancers and their advantages described but have not yet managed to pass clinical trials.

Antigenic essence technology offers the possibility to revitalize the field of whole-cell-based vaccination, as the essence comprises the entire diversity of native cellular antigens. At the same time, the technology allows for precise control and purposeful change of essence composition as well as purification of essence from ballast cellular substances and also addresses issues of major histocompatibility complex restriction. Antigenic essence technology makes it possible to update many cellular vaccines that have already been developed, as well as to develop new ones, therefore introducing a new direction for anticancer vaccination research.
See our latest
scientific paper
Petr G. Lokhov; Elena E. Balashova: "Antigenic Essence: Upgrade of Cellular Cancer Vaccines". Cancers 2021, 13, 774.
Early cancer vaccines include whole-cell formulations, which operate on the principle that you should vaccinate with what you want to develop protection against. Such vaccines have been widely tested in various cancers and their advantages described but have not yet managed to pass clinical trials.

Antigenic essence technology offers the possibility to revitalize the field of whole-cell-based vaccination, as the essence comprises the entire diversity of native cellular antigens. At the same time, the technology allows for precise control and purposeful change of essence composition as well as purification of essence from ballast cellular substances and also addresses issues of major histocompatibility complex restriction. Antigenic essence technology makes it possible to update many cellular vaccines that have already been developed, as well as to develop new ones, therefore introducing a new direction for anticancer vaccination research.
About our company
and technology
Biobohemia, Inc. is a biotechnology company focused on development of cancer vaccines.

Biobohemia's lead technology is cell Antigenic Essence production via proteomics and cell culture technology, and which is a deep upgrade of cellular cancer vaccines. Antigenic essence technology is the revitalization of cellular vaccination, as antigenic essence exhibits all the identifying properties of cancer cells while also allowing for control of composition, purification from ballast substances (cellular 'noise'), and evasion of MHC restrictions. Therefore, antigenic essence technology allows upgading of already discovered cellular compositions, as well as creation new ones.

Our antigenic essence technology platform is behind the development of the potential candidates for cancer vaccine, under the brand name SANTAVACTM, that can be tuned against virtually any solid cancer. Our company is progressing the development of both prevention and therapeutic SANTAVACTM vaccines.
About our company
and technology
Biobohemia, Inc. is a biotechnology company focused on development of cancer vaccines.

Biobohemia's lead technology is cell Antigenic Essence production via proteomics and cell culture technology, and which is a deep upgrade of cellular cancer vaccines. Antigenic essence technology is the revitalization of cellular vaccination, as antigenic essence exhibits all the identifying properties of cancer cells while also allowing for control of composition, purification from ballast substances (cellular 'noise'), and evasion of MHC restrictions. Therefore, antigenic essence technology allows upgading of already discovered cellular compositions, as well as creation new ones.

Our antigenic essence technology platform is behind the development of the potential candidates for cancer vaccine, under the brand name SANTAVACTM, that can be tuned against virtually any solid cancer. Our company is progressing the development of both prevention and therapeutic SANTAVACTM vaccines.